psma-617 and Prostatic-Diseases

psma-617 has been researched along with Prostatic-Diseases* in 1 studies

Trials

1 trial(s) available for psma-617 and Prostatic-Diseases

Article	Year
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of European urology focus, 2021, Volume: 7, Issue:2 LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection. Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Diseases	2021

Article

Year

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of

European urology focus, 2021, Volume: 7, Issue:2

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.

Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Diseases

2021